Saiama Naheed Waqar

机构：Washington University in St. Louis · ORCID：0000-0002-7069-5456

发表论文 312 篇 · 总被引 7241 次 · h-index 41

代表论文

• Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03 (2025 · Journal of Thoracic Oncology · 被引 57)
• Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A (2025 · Journal of Thoracic Oncology · 被引 34)
• First-line (1L) datopotamab deruxtecan (Dato-DXd) + rilvegostomig in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohort 5). (2025 · Journal of Clinical Oncology · 被引 10)
• 8O First-line (1L) datopotamab deruxtecan (Dato-DXd) + durvalumab ± carboplatin in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohorts 2 and 4) (2025 · ESMO Open · 被引 10)
• Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung Cancer (2025 · Journal of Thoracic Oncology · 被引 9)
• CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 ( NRG1 ) Fusions (2025 · JCO Precision Oncology · 被引 5)